JP2017511329A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511329A5
JP2017511329A5 JP2016560389A JP2016560389A JP2017511329A5 JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5 JP 2016560389 A JP2016560389 A JP 2016560389A JP 2016560389 A JP2016560389 A JP 2016560389A JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5
Authority
JP
Japan
Prior art keywords
oxy
amine
dimethylpentan
methyl
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511329A (ja
JP6411541B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023805 external-priority patent/WO2015153720A1/en
Publication of JP2017511329A publication Critical patent/JP2017511329A/ja
Publication of JP2017511329A5 publication Critical patent/JP2017511329A5/ja
Application granted granted Critical
Publication of JP6411541B2 publication Critical patent/JP6411541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560389A 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤 Active JP6411541B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973942P 2014-04-02 2014-04-02
US61/973,942 2014-04-02
US201462061591P 2014-10-08 2014-10-08
US62/061,591 2014-10-08
PCT/US2015/023805 WO2015153720A1 (en) 2014-04-02 2015-04-01 Biaryl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017511329A JP2017511329A (ja) 2017-04-20
JP2017511329A5 true JP2017511329A5 (enExample) 2018-03-15
JP6411541B2 JP6411541B2 (ja) 2018-10-24

Family

ID=52988448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560389A Active JP6411541B2 (ja) 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤

Country Status (27)

Country Link
US (7) US9902722B2 (enExample)
EP (1) EP3126351B1 (enExample)
JP (1) JP6411541B2 (enExample)
KR (1) KR102379518B1 (enExample)
CN (1) CN106458994B (enExample)
AU (1) AU2015240869B2 (enExample)
BR (1) BR112016022298B1 (enExample)
CA (1) CA2944466C (enExample)
CL (1) CL2016002502A1 (enExample)
CY (1) CY1120988T1 (enExample)
DK (1) DK3126351T3 (enExample)
EA (1) EA028942B1 (enExample)
ES (1) ES2700549T3 (enExample)
HR (1) HRP20181899T1 (enExample)
HU (1) HUE041457T2 (enExample)
IL (1) IL248086B (enExample)
LT (1) LT3126351T (enExample)
MX (1) MX2016012829A (enExample)
PE (1) PE20170004A1 (enExample)
PL (1) PL3126351T3 (enExample)
PT (1) PT3126351T (enExample)
RS (1) RS58062B1 (enExample)
SG (1) SG11201608195QA (enExample)
SI (1) SI3126351T1 (enExample)
SM (1) SMT201800665T1 (enExample)
WO (1) WO2015153720A1 (enExample)
ZA (1) ZA201606767B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
KR102379518B1 (ko) * 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
WO2016164295A2 (en) * 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017059085A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—2,2'—聯嘧啶基化合物、其類似物及其使用方法
EP4138844A1 (en) 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
WO2021216441A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
TW202210462A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 (s)-2-胺基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其鹽的製備方法
TW202210461A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種(s)—2—胺基—3—(4—(2,3—二甲基吡啶—4—基)苯基)丙酸甲酯二酸鹽的製備方法
CN117715899A (zh) * 2021-07-15 2024-03-15 西藏海思科制药有限公司 Aak1抑制剂及其用途
CN115872927A (zh) * 2021-09-30 2023-03-31 武汉人福创新药物研发中心有限公司 Aak1抑制剂及其用途
JP2025508781A (ja) 2022-03-01 2025-04-10 レクシコン ファーマシューティカルズ インコーポレイテッド Aak1阻害剤の合成に有用な方法及び化合物
KR20240155293A (ko) * 2022-03-01 2024-10-28 렉시컨 파마슈티컬스 인코퍼레이티드 고체 형태의 (s)-1-((2',6-비스(디플루오로메틸)-[2,4'-바이피리딘]-5-일)옥시)-2,4-디메틸펜탄-2-아민 및 이의 염
US20250197354A1 (en) 2022-03-23 2025-06-19 Teva Pharmaceuticals International Gmbh Solid state forms of lx9211 and salts thereof
CN120202001A (zh) * 2022-11-10 2025-06-24 西藏海思科制药有限公司 一种含aak1抑制剂的药物组合物
CN120344529A (zh) * 2022-12-13 2025-07-18 上海海雁医药科技有限公司 杂环取代的五并六元杂芳基衍生物、其药物组合物及应用与制备方法
WO2024153067A1 (zh) * 2023-01-16 2024-07-25 上海海雁医药科技有限公司 杂环取代的含氮杂环衍生物、其药物组合物及应用与制备方法
WO2024207945A1 (zh) * 2023-04-07 2024-10-10 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
CN118772152A (zh) * 2023-04-07 2024-10-15 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
WO2025092928A1 (zh) * 2023-11-02 2025-05-08 西藏海思科制药有限公司 一种可抑制连接蛋白相关激酶1的化合物、制备及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003286895A1 (en) * 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
MX2008013203A (es) * 2006-04-12 2008-10-22 Wyeth Corp Analogos de anilino-pirimidina fenilo y benzotiofeno.
CA2677096A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
HUE036040T2 (hu) * 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
EP3044226B1 (en) 2013-09-11 2017-09-06 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
CA2937529A1 (en) 2014-01-29 2015-08-06 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
MX2016009352A (es) 2014-01-31 2016-10-13 Bristol Myers Squibb Co Inhibidores de quinasa a base de quinolina.
KR102379518B1 (ko) 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
US20170239249A1 (en) 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017059085A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2020010295A1 (en) 2018-07-06 2020-01-09 Liqui-Box Corporation Dispensing probe for dispensing flowable material

Similar Documents

Publication Publication Date Title
JP2017511329A5 (enExample)
JP2018537408A5 (enExample)
NZ609955A (en) Sgc stimulators
ES2675760T3 (es) Compuestos terapéuticamente activos y métodos de uso de los mismos
JP5367707B2 (ja) Dhodh阻害剤としてのアザビフェニルアミノ安息香酸誘導体
JP2016523977A5 (enExample)
JP2016525076A5 (enExample)
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
JP2016525075A5 (enExample)
US10376510B2 (en) 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
JP2020502111A5 (enExample)
JP2015172062A5 (enExample)
JP2015503571A5 (enExample)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2017530962A5 (enExample)
JP2011503230A5 (enExample)
RU2014124953A (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
CN110139860A (zh) 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
JP2016522232A5 (enExample)
JP2012525395A5 (enExample)
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
JP2013543480A5 (enExample)
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
JP2017523214A5 (enExample)
JP2013500997A5 (enExample)